D1 receptor alleles predict PET metabolic correlates of clinical response to clozapine

A goal of pharmacogenetics is to clarify associations between allelic variation and risk factors in psychiatric illness. We report changes in regional brain metabolism based on dopamine alleles. Treatment-resistant schizophrenic subjects were positron emission tomography scanned with 18F-fluorodeoxyglucose after 5 weeks each of placebo and clozapine treatment. Significant regional brain metabolic effects were found for the D1 receptor genotypes (P<0.05), adjusted for multiple comparisons. Metabolic decreases for the 2,2 genotype but not the 1,2 genotype were observed in all major sectors of the brain, with the exception of the ventral parts of the caudate and putamen. Frontal, temporal, parietal, and occipital neocortices showed decreased metabolism as did the cingulate juxta-allocortex and the parahippocampal allocortex. Decreases were also observed in the thalamus, amygdala, and cerebellum bilaterally. No significant metabolic differences by genotype were observed for D3, 5HT2A, and 5HT2C polymorphisms. In terms of clinical response, the DRD1 2,2 genotype significantly improved with clozapine treatment, demonstrating a 30% decrease in the Brief Psychiatric Rating Scale positive symptoms in contrast to a 7% worsening for the 1,2 genotype (P<0.05). In this preliminary study, brain metabolic and clinical response to clozapine are related to the D1 receptor genotype.

[1]  M Masellis,et al.  A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: association with tardive dyskinesia in schizophrenia , 2000, Molecular Psychiatry.

[2]  P. Good,et al.  Permutation Tests: A Practical Guide to Resampling Methods for Testing Hypotheses , 1995 .

[3]  Cheuk Y. Tang,et al.  Decreasing Striatal 6-FDOPA Uptake with Increasing Duration of Cocaine Withdrawal , 1999, Neuropsychopharmacology.

[4]  M S Buchsbaum,et al.  Striatal metabolic rate and clinical response to neuroleptics in schizophrenia. , 1992, Archives of general psychiatry.

[5]  Fabio Macciardi,et al.  Association of the MscI Polymorphism of the Dopamine D3 Receptor Gene with Tardive Dyskinesia in Schizophrenia , 1999, Neuropsychopharmacology.

[6]  K. Nuechterlein.  Signal detection in vigilance tasks and behavioral attributes among offspring of schizophrenic mothers and among hyperactive children. , 1983, Journal of abnormal psychology.

[7]  A. Hirano,et al.  AN ATLAS OF THE HUMAN BRAIN FOR COMPUTERIZED TOMOGRAPHY. , 1978 .

[8]  M. Martres,et al.  Amino acid substitution in the dopamine D3 receptor as a useful polymorphism for investigating psychiatric disorders , 1992 .

[9]  M Laruelle,et al.  D2 receptors binding potential is not affected by Taq1 polymorphism at the D2 receptor gene , 1998, Molecular Psychiatry.

[10]  M. Iyo,et al.  Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET , 1997, Nature.

[11]  S. Potkin,et al.  Ex uno multi: subtyping the schizophrenic syndrome. , 1982, Biological psychiatry.

[12]  J. Fink,et al.  An MspI polymorphism in the hyman serotonin receptor gene (HTR2): detection by DGGE and RFLP analysis. , 1992, Human molecular genetics.

[13]  G. Sedvall,et al.  D1, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients. , 1995, The American journal of psychiatry.

[14]  P. Holzman,et al.  Eye movements and the search for the essence of schizophrenia , 2000, Brain Research Reviews.

[15]  J. Kane,et al.  Clozapine for the treatment-resistant schizophrenic: results of a US multicenter trial , 1989, Psychopharmacology.

[16]  P. Sokoloff,et al.  Dopamine-related genes and their relationships to monoamine metabolites in CSF , 1996, Biological Psychiatry.

[17]  P. Seeman,et al.  Dopamine receptor pharmacology. , 1994, Trends in pharmacological sciences.

[18]  H. Meltzer,et al.  Relationship between dopaminergic and serotonergic neuronal activity in the frontal cortex and the action of typical and atypical antipsychotic drugs , 1999, European Archives of Psychiatry and Clinical Neuroscience.

[19]  Karl J. Friston,et al.  Comparing Functional (PET) Images: The Assessment of Significant Change , 1991, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[20]  D. Goldman,et al.  Identification, expression, and pharmacology of a Cys23-Ser23 substitution in the human 5-HT2c receptor gene (HTR2C). , 1995, Genomics.

[21]  S. Potkin,et al.  Clozapine effects on glucose metabolic rate in striatum and frontal cortex. , 1994, The Journal of clinical psychiatry.

[22]  A. Mimbacas,et al.  A new polymorphic probe on chromosome 22q (XD6) (D22S313). , 1993, Human molecular genetics.

[23]  M. Reivich,et al.  THE [14C]DEOXYGLUCOSE METHOD FOR THE MEASUREMENT OF LOCAL CEREBRAL GLUCOSE UTILIZATION: THEORY, PROCEDURE, AND NORMAL VALUES IN THE CONSCIOUS AND ANESTHETIZED ALBINO RAT 1 , 1977, Journal of neurochemistry.

[24]  Susan R. George,et al.  Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1 , 1991, Nature.

[25]  E. Hoffman,et al.  TOMOGRAPHIC MEASUREMENT OF LOCAL CEREBRAL GLUCOSE METABOLIC RATE IN HUMANS WITH (F‐18)2‐FLUORO-2‐DEOXY-D‐GLUCOSE: VALIDATION OF METHOD , 1980, Annals of neurology.

[26]  R. Freedman,et al.  Alternative phenotypes for the complex genetics of schizophrenia , 1999, Biological Psychiatry.

[27]  S Pollack,et al.  The resampling method of statistical analysis. , 1994, Psychopharmacology bulletin.

[28]  P. O’Donnell,et al.  D(1) dopamine receptors potentiate nmda-mediated excitability increase in layer V prefrontal cortical pyramidal neurons. , 2001, Cerebral cortex.

[29]  E. Hoffman,et al.  Tomographic measurement of local cerebral glucose metabolic rate in humans with (F‐18)2‐fluoro‐2‐deoxy‐D‐glucose: Validation of method , 1979, Annals of neurology.

[30]  M S Buchsbaum,et al.  Effects of clozapine and thiothixene on glucose metabolic rate in schizophrenia. , 1992, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.

[31]  H. Meltzer.  The Role of Serotonin in Schizophrenia and the Place of Serotonin‐Dopamine Antagonist Antipsychotics , 1995, Journal of clinical psychopharmacology.

[32]  N C Andreasen,et al.  Heritability of BDNF alleles and their effect on brain morphology in schizophrenia. , 1999, American journal of medical genetics.